englitazone

06/01/1998 - "Previous studies have focused on the ability of englitazone to increase insulin sensitivity in various tissues. "
08/01/2005 - "Englitazone administration to late pregnant rats produces delayed body growth and insulin resistance in their fetuses and neonates."
12/01/2007 - "To corroborate the role of IRS-1 in adipose tissue insulin resistance during pregnancy, we treated pregnant rats with the antidiabetic drug englitazone. "
11/01/1990 - "CP 68722 was able to overcome insulin resistance induced by dexamethasone in 3T3-L1 cells. "
10/01/1993 - "We studied the efficacy of two of these agents, pioglitazone and englitazone, in preventing glucocorticoid-induced insulin resistance in rats, and examined the potential role of changes in GLUT4 expression in their action in skeletal muscle. "

12/01/1991 - "Administration of englitazone at 50 mg/kg/d for 8 days did not produce overt hypoglycemia but it lowered basal plasma insulin by 59% and 41% in rats fed ad libitum and fasted overnight on the last day, respectively. "
12/01/1991 - "Antidiabetic agent englitazone enhances insulin action in nondiabetic rats without producing hypoglycemia."
10/01/1990 - "Administration of englitazone at 5-50 mg.kg-1.day-1 lowered plasma glucose and insulin dose dependently without producing frank hypoglycemia in either the diabetic or nondiabetic lean animals. "

11/01/1990 - "We compared the effect of CP 68722 with the sulfonylureas, the primary drugs used in the treatment of non-insulin-dependent diabetes mellitus (NIDDM). "
10/01/1990 - "Thus, englitazone has 1) insulinomimetic and insulin-enhancing actions in vitro and 2) glucose-, insulin-, triglyceride-, and cholesterol-lowering properties in an animal model of non-insulin-dependent diabetes mellitus (NIDDM) in which sulfonylureas have little or no effect. "

01/01/2000 - "The two compounds that were selected as development candidates (englitazone and darglitazone) did not produce cataracts in rats exposed daily for 3 months. "